pharmaphorum

MAY 24, 2022

Data is the powerhouse of the pharmaceutical sector. It powers drug discovery, clinical trials, and operational performance. But sizeable reservoirs of data remain unseen and untapped to commercial operations, allowing insights, opportunities, and efficiencies to leak away. Organisations are missing out on the ability to harness their data to energise precision marketing and transform commercial performance.

Customer Service 112

Customer Service 112

Outsourcing Pharma

MAY 24, 2022

The drug company, which uses artificial intelligence to discover and advance repurposed drugs, is harnessing the technology to find a treatment for Crohnâs.

91

91

pharmaphorum

MAY 24, 2022

Industrial action at several GlaxoSmithKline manufacturing plants in the UK has been called off, after an improved pay deal was accepted by the Unite union. Unite said last month it was calling for strike by GSK workers for the first time in the company’s history, saying a “derisory” 2.75% pay increase was in fact a pay cut in real terms given the rising rate of inflation in the UK, currently at around 9%.

98

98

Pharma Times

MAY 24, 2022

Less invasive procedure offers an equally effective alternative for heart condition patients

57

57

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

pharmaphorum

MAY 24, 2022

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by the FDA on the new indication. The drugmaker filed Vraylar (cariprazine) as an add-on to conventional antidepressant therapy in people with MDD who may be struggling to control symptoms using the antidepressant alone in February, with a decision expected by the end of the year.

FDA 65

FDA 65

Pharma Marketing Network

MAY 24, 2022

Tune in to this episode of the Pharma Marketing Podcast with Bharti Rai, Novartis VP, Chief Commercial Operations, Insight, Analytics Officer Data & Digital, for a deeper dive into what’s ahead for 1st and 3rd party data, insights, analytics & digital data. The post What’s Ahead for 1st and 3rd party data, Insights, Analytics & Digital Data Video appeared first on Pharma Marketing Network.

52

52

Outsourcing Pharma

MAY 24, 2022

The virtual research organization has developed digital instruments designed for assessing stools and recording crying episodes in pediatric clinical studies.

52

52

pharmaphorum

MAY 24, 2022

As healthcare evolves to become more consumer-centric, the value of social health – the dynamic, real-time action people take to find meaningful connections and share information that impact the health journey – becomes more essential. When properly executed, social health interactions can be leveraged to create mutually beneficial impact for both patients and pharma.

52

52

Outsourcing Pharma

MAY 24, 2022

The digital medicine solutions developer has received $300m in a Series D investment round, which will be used to help scale up its virtual care offerings.

52

52

pharmaphorum

MAY 24, 2022

Value is a tricky concept to capture accurately. Given the diverse and complex world that we live in, different people will often hold contrasting views of what constitutes value. Identifying and measuring value is a particularly interesting quandary for life sciences companies, as inevitably each of these viewpoints will interact with the industry in some way, shape or form.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharma Times

MAY 24, 2022

Companies say that three-dose vaccine for children aged six months to five years old is 80% effective at preventing illness

Vaccines 48

Vaccines 48

pharmaphorum

MAY 24, 2022

The pharma industry is becoming an increasingly hot commodity for cybercriminals. In recent years, digital adoption has accelerated at a rapid pace, with companies racing to integrate cloud-based platforms and telehealth services to expand the delivery of modern healthcare. Combined with the sudden arrival of COVID-19, this perfect storm of events handed cybercriminals an opportunity to exploit weaknesses in fledging systems and processes.

Hospitals 145

Hospitals Vaccines 145

pharmaphorum

MAY 24, 2022

Shares in US biotech Nymox Pharma have plunged after the company announced the FDA had refused to accept its marketing application for its drug candidate for benign prostatic hyperplasia (BPH), a common condition affecting older men. The regulator has asked for additional longer-term safety data on the drug, called fexapotide triflutate, which was submitted for approval in March, according to a Nymox statement on the decision.

FDA 59

FDA Communication 59

pharmaphorum

MAY 24, 2022

The World Health Organization has said the current outbreak of monkeypox is the largest ever recorded outside sub-Saharan Africa, with cases rising above the 100-mark a few days ago and the UK top of the table with 56 as of yesterday. Top of the list of concerns is how the virus – which does not spread easily between humans and requires skin-to-skin contact – is spreading so quickly in so many countries in Europe, the Americas and Australia where the disease is not endemic.

Vaccines 95

Vaccines FDA Labelling 95

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA